Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 3/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 9/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 9/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8528137 | 0.87 | MIF (0.42) | MIFADRA1AMTNR1AMTNR1BACHE | |
| SCHEMBL8903352 | 0.84 | MIF (0.42) | MIFADRA1AHTTMTNR1AMTNR1B | |
| SCHEMBL8528110 | 0.80 | MIF (0.39) | MIFADRA1AHTTMTNR1AMTNR1B | |
| SCHEMBL8531354 | 0.79 | HTR1A (0.41) | MIFADRA1AHTTMTNR1AMTNR1B | |
| SCHEMBL8902583 | 0.77 | ADRA1A (0.45) | ADRA1AACHE | |
| SCHEMBL8527142 | 0.75 | MIF (0.46) | MIFADRA1AHTTMTNR1AMTNR1B | |
| SCHEMBL8527073 | 0.74 | ADRA1A (0.42) | ADRA1AMTNR1AMTNR1BACHECYP1A2 | |
| SCHEMBL8531892 | 0.72 | ADRA1A (0.41) | ADRA1AMTNR1AMTNR1BACHE | |
| SCHEMBL8903292 | 0.72 | ADRA1A (0.41) | MIFADRA1AHTTMTNR1AMTNR1B | |
| SCHEMBL9522182 | 0.71 | MIF (0.41) | MIFADRA1AMTNR1AMTNR1BACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1991019725-A2 | HETEROCYCLIC ANTHRACYCLIONE AND ANTHRACYCLINE ANALOGS | BIOCHEM PHARMA INC. (CA) | 1991-12-26 | — | — | WO | claimed |
| US-5593970-A | ANTITUMOR AND ANTCARCINOGENIC AGENTS; TRETMENT OF CANCEROUS BONE MARROW BEFORE REGRAFTING | BIOCHEM PHARMA INC. (CA) | 1997-01-14 | — | — | US | disclosed |
| WO-1991019725-A2 | HETEROCYCLIC ANTHRACYCLIONE AND ANTHRACYCLINE ANALOGS | BIOCHEM PHARMA INC. (CA) | 1991-12-26 | — | — | WO | disclosed |